Abivax Stock-Based Compensation Growth & History (ABVX)

Abivax's stock-based compensation was €35.4M for fiscal 2025.

View full Abivax company overview

Abivax annual stock-based compensation history

Abivax annual stock-based compensation

Fiscal yearPeriod endedStock-based compensationChangeGrowth
20252025-12-31€35.4M€15.2M+75.02%
20242024-12-31€20.2M€12.0M+147.27%
20232023-12-31€8.2M€7.0M+602.66%
20222022-12-31€1.2M€336,000+40.58%
20212021-12-31€828,000

Abivax stock-based compensation trends

Between the periods ended 2021-12-31 and 2025-12-31, Abivax's stock-based compensation increased from €828,000 to €35.4M, a change of €34.6M. The latest reported quarter, Q1 2026, shows €22.6M.

About the metric

What stock-based compensation means

Stock-based compensation is the expense associated with equity awards such as restricted stock and employee options. It is a non-cash expense when recognized, but it can dilute existing shareholders unless offset by share repurchases.

Calculation and source

SEC-reported stock-based compensation

TickerStat standardizes share-based compensation reported in company SEC filings. The history shows recognized compensation expense or its cash-flow-statement adjustment, not the grant-date value of new awards or a forecast of future dilution. Fiscal periods can differ from calendar years, so exact period-end dates are included.

Review Abivax source filings ↗

Community posts

It’s quiet here.

No posts about ABVX yet. Start the conversation.

Write the first post